News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Antares Pharma, Inc. (AIS) Enters Into An Exclusive U.S. Promotion And Marketing Agreement With LEO Pharma For OTREXUP™ In Dermatology


11/14/2013 9:26:16 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ: ATRS) today announced an exclusive promotion and marketing agreement with LEO Pharma for detailing OTREXUP™ (methotrexate) to dermatologists for symptomatic control of severe recalcitrant psoriasis in adults. Under the terms of the agreement, Antares may receive up to a total of $20 million in milestone payments including an upfront payment of $5 million. Antares Pharma will record all product revenue associated with future dermatology prescriptions and pay LEO Pharma a percentage of OTREXUP™ net sales generated in dermatology. LEO Pharma will be responsible for promotion and marketing activities in dermatology.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES